Parkinson´S Disease Drug Market Size, Share, Growth Analysis, By Drug Class (Decarboxylase Inhibitors, Dopamine Agonists), By Administration (Oral, Injection), By Age, By Region - Industry Forecast 2025-2032
파킨슨병 치료제 세계 시장 규모는 2023년 46억 달러로 평가되었고, 2024년 50억 9,000만 달러에서 2032년에는 113억 9,000만 달러로 성장해 예측기간(2025-2032년) CAGR은 10.6%로 성장할 전망입니다.
세계 파킨슨병 치료제 시장은 도파민 생산이 저하되고, 떨림이나 경직과 같은 증상을 특징으로 하는 이 신경질환을 앓고 있는 환자가 현재 1,000만명을 넘어서 큰 성장이 예상되었습니다. 이 질병의 유병률이 상승하고 효과적인 증상 관리의 필요성이 계속 증가하고 있는 가운데, 시장은 병용 요법, 서방형 약제, 유전자 치료의 진보, 정부로부터의 지원금에 대한 관심 증가로 이익을 얻고 있습니다. 게다가 노령화, 건강 관리 시스템 개선, 지속적인 연구 개발 등의 요인이 시장 개척을 뒷받침하고 있습니다. 브랜드 의약품의 특허 만료과 신규 치료의 강력한 파이프라인은 예측 기간 동안 업계 기업에게 유리한 기회를 제공하여 시장 잠재력을 더욱 높여줍니다.
목차
소개
조사 방법
- 정보 조달
- 2차 데이터와 1차 데이터의 방법
- 시장 규모 예측
- 시장의 전제조건과 제한
주요 요약
- 세계 시장 전망
- 공급과 수요 동향 분석
- 부문별 기회 분석
시장 역학과 전망
- 시장 개요
- 시장 규모
- 시장 역학
- Porter's Five Forces 분석
주요 시장 인사이트
- 중요성공요인
- 경쟁도
- 주요 투자 기회
- 시장 생태계
- 시장의 매력 지수(2024년)
- PESTEL 분석
- 거시경제지표
- 밸류체인 분석
- 가격 분석
파킨슨병 치료제 시장 규모 : 약품 클래스별
- 시장 개요
- 탈탄산효소 억제제
- 도파민 작용제
- COMT 억제제
- MAO-B 억제제
- 기타
파킨슨병 치료제 시장 규모 : 투여방법별
파킨슨병 치료제 시장 규모 : 연령별
파킨슨병 치료제 시장 규모
- 북미
- 유럽
- 아시아태평양
- 라틴아메리카
- 중동 및 아프리카
- GCC 국가
- 남아프리카
- 기타 중동 및 아프리카
경쟁 정보
- 상위 5개사 비교
- 주요 기업의 시장 포지셔닝(2024년)
- 주요 시장 기업이 채용한 전략
- 시장의 최근 동향
- 기업의 시장 점유율 분석(2024년)
- 주요 기업의 기업 프로파일
- 기업 개요
- 제품 포트폴리오 분석
- 부문별 점유율 분석
- 수익의 전년 대비 비교(2022-2024)
주요 기업 프로파일
- AbbVie Inc.(USA)
- Novartis AG(Switzerland)
- Teva Pharmaceutical Industries Ltd.(Israel)
- UCB SA(Belgium)
- GlaxoSmithKline plc(UK)
- Merck & Co., Inc.(USA)
- Boehringer Ingelheim(Germany)
- Lundbeck A/S(Denmark)
- Acadia Pharmaceuticals Inc.(USA)
- Sun Pharmaceutical Industries Ltd.(India)
- Amneal Pharmaceuticals, Inc.(USA)
- Supernus Pharmaceuticals, Inc.(USA)
- Kyowa Kirin Co., Ltd.(Japan)
- Orion Corporation(Finland)
- Neurocrine Biosciences, Inc.(USA)
- Acorda Therapeutics, Inc.(USA)
- Ipsen SA(France)
- Luye Pharma Group(China)
- NeuroDerm Ltd.(Israel)(acquired by Mitsubishi Tanabe Pharma)
- Revance Therapeutics, Inc.(USA)
결론과 권장사항
JHS
Global Parkinson'S Disease Drug Market size was valued at USD 4.6 billion in 2023 and is poised to grow from USD 5.09 billion in 2024 to USD 11.39 billion by 2032, growing at a CAGR of 10.6% during the forecast period (2025-2032).
The global Parkinson's disease drug market is poised for significant growth, driven by over 10 million individuals currently affected by this neurological disorder, characterized by declining dopamine production and symptoms like tremors and stiffness. As the disease's prevalence rises and the need for effective symptom management continues to grow, the market is benefiting from increased interest in combination therapies, extended-release medications, gene therapy advancements, and supportive government funding. Additionally, factors such as an aging population, improved healthcare systems, and ongoing research and development are bolstering market expansion. The expiration of patents for branded drugs and a strong pipeline of new treatments present lucrative opportunities for industry players during the forecast period, further enhancing the market's potential.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Parkinson'S Disease Drug market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Parkinson'S Disease Drug Market Segmental Analysis
Global Parkinson'S Disease Drug Market is segmented by drug class, administration, age and region. Based on drug class, the market is segmented into decarboxylase inhibitors, dopamine agonists, COMT inhibitors, MAO-b inhibitors and others. Based on administration, the market is segmented into oral, injection and transdermal. Based on age, the market is segmented into < 50 years and > 50 years. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Parkinson'S Disease Drug Market
The global Parkinson's Disease drug market is significantly influenced by several key drivers. Foremost among them is the growing aging population alongside the escalating incidence of Parkinson's disease. As the demographic landscape shifts with an increasing number of elderly individuals, the prevalence of neurological disorders, including Parkinson's, is on the rise. This surge in patient numbers directly correlates with a heightened demand for effective treatment options, thus propelling the market's growth. As a result, this dynamic is anticipated to positively impact the expansion of the Parkinson's Disease drug market worldwide throughout the forecast period.
Restraints in the Global Parkinson'S Disease Drug Market
The global market for Parkinson's disease drugs faces significant restraints primarily due to the high costs associated with treatment. As the prevalence of Parkinson's disease continues to rise, the financial burden on patients, families, and healthcare systems is becoming increasingly pronounced. This economic strain often poses a barrier to accessing necessary treatments and medications, thereby inhibiting the overall growth of the market. Consequently, the prohibitive expense of managing Parkinson's disease is anticipated to serve as a critical challenge for market expansion throughout the forecast period, impacting both patient care and the availability of new therapeutic options.
Market Trends of the Global Parkinson'S Disease Drug Market
The Global Parkinson's Disease Drug market is experiencing substantial growth, driven by a notable surge in research and development funding from both government and corporate sectors aimed at advancing treatment options. This trend is propelling pharmaceutical companies to innovate and introduce new therapeutic drugs that address symptom management and disease modification. Increasing awareness and diagnosis of Parkinson's disease, coupled with a rising geriatric population, further catalyze market expansion. As investments in novel drug development grow, the market is poised for sustained growth, reflecting the increasing commitment to improving patient outcomes and enhancing the quality of life for those affected by Parkinson's disease.
Table of Contents
Introduction
- Objectives of the Study
- Scope of the Report
- Definitions
Research Methodology
- Information Procurement
- Secondary & Primary Data Methods
- Market Size Estimation
- Market Assumptions & Limitations
Executive Summary
- Global Market Outlook
- Supply & Demand Trend Analysis
- Segmental Opportunity Analysis
Market Dynamics & Outlook
- Market Overview
- Market Size
- Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
- Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers
Key Market Insights
- Key Success Factors
- Degree of Competition
- Top Investment Pockets
- Market Ecosystem
- Market Attractiveness Index, 2024
- PESTEL Analysis
- Macro-Economic Indicators
- Value Chain Analysis
- Pricing Analysis
Global Parkinson's Disease Drug Market Size by Drug Class & CAGR (2025-2032)
- Market Overview
- Decarboxylase Inhibitors
- Dopamine Agonists
- COMT Inhibitors
- MAO-B Inhibitors
- Others
Global Parkinson's Disease Drug Market Size by Administration & CAGR (2025-2032)
- Market Overview
- Oral
- Injection
- Transdermal
Global Parkinson's Disease Drug Market Size by Age & CAGR (2025-2032)
- Market Overview
- < 50 Years
- >50 Years
Global Parkinson's Disease Drug Market Size & CAGR (2025-2032)
- North America (Drug Class, Administration, Age)
- Europe (Drug Class, Administration, Age)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Drug Class, Administration, Age)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Drug Class, Administration, Age)
- Brazil
- Rest of Latin America
- Middle East & Africa (Drug Class, Administration, Age)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2024
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2024
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)
Key Company Profiles
- AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- UCB S.A. (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Boehringer Ingelheim (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lundbeck A/S (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Acadia Pharmaceuticals Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceutical Industries Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amneal Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Supernus Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Kyowa Kirin Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Orion Corporation (Finland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Neurocrine Biosciences, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Acorda Therapeutics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ipsen S.A. (France)
- Company OvervSiew
- Business Segment Overview
- Financial Updates
- Key Developments
- Luye Pharma Group (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- NeuroDerm Ltd. (Israel) (acquired by Mitsubishi Tanabe Pharma)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Revance Therapeutics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Conclusion & Recommendations
